Differences

This shows you the differences between two versions of the page.

--- accelerating_covid-19_therapeutic_interventions_and_vaccines [2022/04/02 20:01]
liam [Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)]
+++ accelerating_covid-19_therapeutic_interventions_and_vaccines [2023/07/02 20:47] (current)
liam
@@ Line 1: / Line 1: @@
 ====== Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) ======
-{{ :eb7x_bbu4aygyfz.jpeg?200|}}
+{{ ::29dce7bcceddea25d429490fda87008d.png?200|}}
 On April 17, 2020, the [[National Institutes of Health]] (NIH) announced the [[Accelerating COVID-19 Therapeutic Interventions and Vaccines]] (ACTIV) [[public-private partnership]] to develop a coordinated research strategy for prioritizing and speeding up development of [[COVID-19 vaccines]] and [[pharmaceutical products]].((//ACTIV.// National Institutes of Health (NIH). Retrieved April 1, 2022, from https://archive.ph/8eMTV))
@@ Line 34: / Line 34: @@
 | [[Marc Charette]]  | [[National Heart, Lung, and Blood Institute]]  | Program Director; Division of Cardiovascular Diseases  |
 | [[Tomas Cihlar]]  | [[pharmaceutical_companies:Gilead Sciences]]  | Vice President and Head of Virology  |
-| [[Christine Colvis]]  | [[National Center for Advancing Translational Sciences]]  | Director, Drug Development Partnership Programs]]  |
+| [[Christine Colvis]]  | [[National Center for Advancing Translational Sciences]]  | Director, Drug Development Partnership Programs  |
 | [[Michael Diamond]]  | [[Washington University School of Medicine in St. Louis]]  | The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology  |
 | [[Ken Duncan]]  | [[Bill & Melinda Gates Foundation]]  | Deputy Director, Discovery – Therapeutics  |